LUCENTIS (ranibizumab injection) Intravitreal Injection. Initial U.S. Approval: 2006

Category: .

LUCENTIS (ranibizumab injection) Intravitreal Injection. Initial U.S. Approval: 2006

LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
• Neovascular (Wet) Age-Related Macular Degeneration (AMD)
• Macular Edema Following Retinal Vein Occlusion (RVO)
• Diabetic Macular Edema (DME)
Single-use glass vial designed to provide 0.05 mL for intravitreal injections:
• 10 mg/mL solution (LUCENTIS 0.5 mg)
• 6 mg/mL solution (LUCENTIS 0.3 mg)
Manufactured By: Genentech
Prescribing Information URL: Click Here

Access to LUCENTIS (ranibizumab injection) Intravitreal Injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.